3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
3
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Interventions
Azacitidine
3
ruxolitinib
2
abiraterone
2
Vorinostat
2
Molecular Diagnostic Techniques
2
Doxorubicin
2
venetoclax
1
trametinib
1
rucaparib
1
regorafenib
1
ponatinib
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
olaparib
1
neratinib
1
motexafin gadolinium
1
lorlatinib
1
lenvatinib
1
idelalisib
1
enzalutamide
1
entrectinib
1
enasidenib
1
durvalumab
1
dehydroftorafur
1
darolutamide
1
dacomitinib
1
dabrafenib
1
copanlisib
1
cobimetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Immunotherapy
×
Myeloid
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled